Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402687 · ClinicalTrials.gov registry record
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 181
- Enrollment target
NCT01402687 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 181 participants.
The verdict
NCT01402687 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 181 participants
- Enrollment target
Study Summary
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The study seeks to understand if different forms of genes result in an increased risk of sores in the mouth and esophagus.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402687
The ClinicalTrials.gov registry entry for NCT01402687 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01402687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01402687 about?
NCT01402687 is a clinical study titled "SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)". The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The study seeks to understand if different forms of genes result in an increased risk of sores in the mou...
What is the current status of trial NCT01402687?
This trial is currently completed. The enrollment target is 181 participants. The study started on 2010-10. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT01402687?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.